Tag: Pharnext
PHARNEXT: Adjustment of the nominal value – 03/20/2024 at 7:30 p.m.
PARIS, France, March 20, 2024 at 7:00 p.m. (CET) – Pharnext SCA (FR001400N1P4 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext: trading suspended pending a next update
(CercleFinance.com) – Pharnext announced on Wednesday that it had requested the suspension of its listing on the Paris Stock Exchange pending a future update on its operational, strategic and financial…
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 03/01/2024 at 6:00 p.m.
PARIS, France, 1 er March 2024 at 6 p.m. (CET) – Pharnext SCA (FR001400N1P4 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for…
Pharnext advances analysis of data from the pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A
By Hector Chaunu Published on 02/28/2024 at 9:00 a.m. Photo credit © ChaunuPictures (Boursier.com) — Pharnext SCA,…
The fate of Pharnext suspended on the PXT3003 trial carried out in China
(AOF) – Pharnext announces that in accordance with its commitment dated January 17, it has stopped all its operational expenses, the time to complete the additional analyzes of the Premier…
PHARNEXT: Adjustment of the nominal value – 02/20/2024 at 6:00 p.m.
PARIS, France, February 20, 2024 at 6:00 p.m. (CET) – Pharnext SCA (FR001400N1P4 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
PHARNEXT: Fundraising of 250 thousand euros – 02/20/2024 at 6:00 p.m.
PARIS, France, February 20, 2024 at 6 p.m. (CET) – Pharnext SCA (FR001400N1P4 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext raises 250,000 euros and reduces its capital
(AOF) – Pharnext announces a fundraising of 250,000 euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. This biotech (developing new therapies for neurodegenerative diseases without satisfactory…
Pharnext raises 250,000 euros and reduces its capital – 02/20/2024 at 6:15 p.m.
(AOF) – Pharnext announces a fundraising of 250,000 euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. This biotech (developing new therapies for neurodegenerative diseases without satisfactory…
PHARNEXT: Update following the general meeting of shareholders convened on February 15, 2024 – 02/15/2024 at 8:30 p.m.
PARIS, France, February 15, 2024 at 8:30 p.m. (CET) – Pharnext SCA (FR001400N1P4 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 02/02/2024 at 6:00 p.m.
PARIS, France, February 2, 2024 at 6 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative…
PHARNEXT: Fundraising of 250 thousand euros – 01/31/2024 at 7:00 p.m.
PARIS, France, January 31, 2024 at 7 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…